In breast cancer cohorts, variant alleles of SLC22A16 (rs714368) were found to be related to higher exposure levels of doxorubicin and doxorubicinol [6] and dose delays by anthracycline toxicities (lower with rs714368, rs6907567, rs723685 and higher with rs12210538) [7]. The gene discussed is SLC22A16; the disease is breast carcinoma.